SelectScience
Join Free
Accelerating Science
NewsClinical Diagnostics

ImpediMed earns Frost & Sullivan 2025 Technology Innovation Leadership Award

This award has been for ImpediMed's support in the Point-of-Care Bioimpedance Spectroscopy Industry

21 Jan 2025

Industry news

ImpediMed has announced that it has been awarded the Frost & Sullivan 2025 North American Technology Innovation Leadership Award in the Point-of-Care Bioimpedance Spectroscopy Industry. The award recognizes ImpediMed's commitment to improving long-term patient outcomes through its SOZO® Digital Health Platform, a non-invasive bioimpedance spectroscopy (BIS) solution to address unmet healthcare needs through fluid and body composition point-of-care patient monitoring, particularly in breast cancer-related lymphedema (BCRL).

As a supporter in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared BIS technology for the clinical assessment of BCRL supported by a large randomized clinical trial and multiple clinical practice guidelines.

BIS provides a non-invasive, quick, and highly sensitive method for detecting fluid changes in the body. By sending a small electrical current through the body to measure resistance, BIS can identify subclinical lymphedema long before visible symptoms appear.

A landmark clinical trial has demonstrated the effectiveness of ImpediMed's BIS technology in preventing chronic lymphedema among breast cancer patients. The PREVENT trial, tracking over 1,200 patients across U.S. and Australian healthcare facilities, showed that early detection using BIS technology prevented progression to chronic lymphedema in 92% of cases. These results validate SOZO's potential as a standard preventive screening tool in oncology clinics worldwide.

"ImpediMed's bioimpedance spectroscopy solution differentiates fluid types with high precision, offering an L-Dex® score to detect early changes in the fluid for clinical intervention in breast cancer-related lymphedema, body composition to measure muscle and fat loss, and HF-Dex to support the management of heart failure," said Isai Pratha Karthik Ph.D., Senior Research Analyst with Frost & Sullivan. "This precision is due to ImpediMed's refined approach to measure impedance at 256 different frequencies up to 1,000 KHz. These accurate measurements provide a comprehensive view of fluid and tissue composition and help clinicians make efficient, data-driven decisions."

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Tags

Point-of-CarePoint-of-Care Testing (POCT) or Near Patient Testing (NPT) products are available for urine, blood and other clinical chemistry analyses. POCT includes: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing (PT / INR), rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Breast CancerBreast cancer is a type of cancer that begins in the cells of the breast and can spread to other parts of the body. Early detection, accurate diagnosis, and targeted treatments are essential for improving patient outcomes. Browse our peer-reviewed product directory to find the best breast cancer research and diagnostic tools, compare products, check reviews, and get pricing directly from manufacturers.

Related articles